Akero Therapeutics Inc expected to post a loss of 97 cents a share - Earnings Preview

Akero Therapeutics

07/05/2025 13:42

Akero Therapeutics Inc AKRO.OQ AKRO.O is expected to show no change in quarterly revenue when it reports  results on May 9 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Akero Therapeutics Inc is for a loss of 97 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Akero Therapeutics Inc is $77.50​, above​ its last closing price of $42.02. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-1.17
-1.15
-0.99
Beat
14.1
Sep. 30 2024
-0.91
-0.90
-1.05
Missed
-16.2
Jun. 30 2024
-0.86
-0.90
-0.81
Beat
9.9​
Mar. 31 2024
-0.96
-0.95
-0.90
Beat
5.5
​​Dec. 31 2023
-0.91
-0.86
-0.99
Missed
-14.9
Sep. 30 2023
-0.69
-0.68
-0.71
Missed
-4.2​
Jun. 30 2023
-0.62
-0.63
-0.60
Beat
4.5
Mar. 31 2023
-0.66
-0.67
-0.55
Beat
18.2

This summary was machine generated May 7 at 12:42 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)